BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30394930)

  • 1. Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases.
    Perez PM; Hope TA; Behr SC; van Zante A; Small EJ; Flavell RR
    Clin Nucl Med; 2019 Jan; 44(1):e28-e32. PubMed ID: 30394930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Prostate-Specific Membrane Antigen-Avid Metastatic Lung Nodule From Primary Prostatic Adenocarcinoma.
    Shetty D; Loh H; Bui C; Mansberg R; Hadjashrafi A; Do V
    Clin Nucl Med; 2016 Oct; 41(10):776-8. PubMed ID: 27556788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate Cancer Pulmonary Metastasis Presenting as a Ground-Glass Pulmonary Nodule on 68Ga-PSMA-11 PET/CT.
    Lubin DJ; Holden SB; Rettig MB; Reiter RE; King CR; Lee JM; Wallace DW; Calais J
    Clin Nucl Med; 2019 May; 44(5):e353-e356. PubMed ID: 30789399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.
    Acar E; Kaya GÇ
    Clin Nucl Med; 2019 Jan; 44(1):53-54. PubMed ID: 30325820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 68Ga-PSMA Avid Primary Adenocarcinoma of the Lung With Complementary Low 18F-FDG Uptake.
    Jochumsen MR; Gormsen LC; Nielsen GL
    Clin Nucl Med; 2018 Feb; 43(2):117-119. PubMed ID: 29261620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.
    Parida GK; Tripathy S; Datta Gupta S; Singhal A; Kumar R; Bal C; Shamim SA
    Clin Nucl Med; 2018 Apr; 43(4):248-249. PubMed ID: 29474196
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Damjanovic J; Janssen JC; Furth C; Diederichs G; Walter T; Amthauer H; Makowski MR
    Cancer Imaging; 2018 May; 18(1):20. PubMed ID: 29769114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solitary PSMA-Positive Pulmonary Metastasis in Biochemical Relapse of Prostate Cancer.
    Große Hokamp N; Kobe C; Linzenich E; Maintz D; Drzezga A
    Clin Nucl Med; 2017 May; 42(5):406-407. PubMed ID: 28195907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncommon Penio-Scrotal Metastases of Prostate Cancer Detected on 68Ga PSMA PET/CT.
    Seniaray N; Verma R; Khanna S; Belho E; Malik D
    Clin Nucl Med; 2019 May; 44(5):424-425. PubMed ID: 30829866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidental Metastatic Melanoma Identified on 68Ga-Prostate-Specific Membrane Antigen PET/CT for Metastatic Prostate Cancer.
    Snow HA; Hofman MS; Mitchell CA; Gyorki DE; Smith MJF
    Clin Nucl Med; 2018 Jul; 43(7):509-511. PubMed ID: 29742609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-Specific Membrane Antigen Expression in Adrenocortical Carcinoma on 68Ga-Prostate-Specific Membrane Antigen PET/CT.
    Arora S; Damle NA; Aggarwal S; Passah A; Behera A; Arora G; Bal C; Tripathi M
    Clin Nucl Med; 2018 Jun; 43(6):449-451. PubMed ID: 29578871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
    Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
    Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-Specific Membrane Antigen-Negative Metastases-A Potential Pitfall in Prostate-Specific Membrane Antigen PET.
    Noto B; Auf der Springe K; Huss S; Allkemper T; Stegger L
    Clin Nucl Med; 2018 Jun; 43(6):e186-e188. PubMed ID: 29659383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
    Lin CY; Lee MT; Lin CL; Kao CH
    Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
    Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
    Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidental Detection of Metastatic Malignant Melanoma on 68Ga-Prostate-Specific Membrane Antigen PET/CT Imaging: Correlative Imaging With FDG PET/CT and Review of the Literature.
    Anconina R; Hod N; Levin D; Ezroh Kazap D; Lantsberg S
    Clin Nucl Med; 2018 Mar; 43(3):204-206. PubMed ID: 29293137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous uptake of
    Hu Y; Wang P; Dai W
    BMC Pulm Med; 2023 Mar; 23(1):73. PubMed ID: 36882747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiphasic
    Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
    J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.